Formulation Development
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701…
TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics
TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….
Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced earning a $15-million clinical milestone payment from Gilead Sciences, Inc. under the exclusive license agreement for….
Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble….
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. recently announced that setmelanotide received Breakthrough Therapy Designation from the US FDA for the treatment of hypothalamic obesity. The FDA's Breakthrough Therapy…
Processa Successfully Identifies Next-Generation Capecitabine Dosage Regimens for Phase 2B Trial
Processa Pharmaceuticals, Inc. recently announced positive results from its ongoing Next-Generation Capecitabine (NGC) Phase 1B trial. The data collected has allowed Processa to estimate the…
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
Eterna Therapeutics Inc. recently announced it has entered into a sponsored research agreement with Michael Andreeff, MD, PhD, Professor of Leukemia at The University of Texas MD Anderson Cancer Center (MD Anderson)…..
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of a Novel Oral Immune Checkpoint Inhibitor
Teon Therapeutics recently announced the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral…
Vaccitech Doses First Patients in Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate
Vaccitech plc recently announced the dosing of the first patients in HBV003, a Phase 2b clinical trial designed to further evaluate the safety and efficacy…
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes & Completion of Phase 1 Healthy Volunteer Portion of Phase 1/2 Study
Biomea Fusion, Inc. recently announced the dosing of the first patient with type 2 diabetes in the Phase 2 portion of COVALENT-111, a Phase 1/2…
WHITEPAPER WORKSHOP - Soft Mist Inhalers
Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition…..
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent BioSolutions
SAB Biotherapeutics recently announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Emergent will provide….
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation…
PLATFORM TECHNOLOGY - Versamune®: A New Generation of Cancer Immunotherapies
Dr. Joe Dervan says the unique ability of Versamune® to modulate and enhance numerous critical steps required for an effective clinically relevant immune response and to be combined with targeted antigens found on tumor cells offers several exciting opportunities to treat a variety of cancers.
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells & Hair Follicles
Aileron Therapeutics recently presented detailed results from its completed Phase 1 study of ALRN-6924 in healthy volunteers at the EORTC-NCI-AACR International Conference on Molecular Targets…
VacV Biotherapeutics Emerges From Stealth Mode to Bring Ground-Breaking Cancer Immunotherapies to the Clinic
VacV Biotherapeutics recently emerged from stealth mode to advance its promising pipeline of preclinical assets with best-in-class potential, toward the clinic…..
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
eFFECTOR Therapeutics, Inc. recently announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized…
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 & BDTX-4933
Black Diamond Therapeutics, Inc. recently announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organisation for…
WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development
Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more….
Symeres Acquires Exemplify BioPharma, Further Strengthening its Strategic Foothold in the US
Symeres recently announced the acquisition of Exemplify BioPharma, a US based CRO that provides integrated drug development services in Process & Analytical Chemistry and….
